The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials, and patients that received the treatment “were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’) over the course of the treatment period compared to those receiving placebo,” Synairgen claimed.
The study has not yet been published in a peer-reviewed journal, nor the full data made publicly available, however.
The drug, SNG001, is a formulation of a naturally-occurring antiviral protein called interferon beta inhaled directly into the lungs, in the hope of stimulating an immune response. The treatment is aimed at preventing infected patients deteriorating from requiring oxygen to being placed on a ventilator.
“This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of hospitalized Covid-19 patients,” said Synairgen CEO Richard Marsden.
“Our efforts are now focused on working with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible.”
The double-blind placebo-controlled trial studied 101 patients from nine specialist hospital sites in the U.K. between March 30 and May 27.
The trial’s chief investigator, Professor Tom Wilkinson, lauded a “momentous coordinated effort” and said the results confirmed researchers’ belief that interferon beta has “huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact.”
Synairgen will now have to present the findings to regulators around the world, and will hope to follow antiviral drug remdesivir in receiving emergency approval from the British government.
British investment bank FinnCap tripled Synairgen’s target price from 120p per share to 360p per share in response to the news.